Results 231 to 240 of about 27,639 (307)
Overlapping mycoses in a case of Seborrheic dermatitis with coexistent Malassezia folliculitis. [PDF]
Sasikumar J, Das SP, Shenoy MM.
europepmc +1 more source
Putative lotilaner/milbemycin‐induced Stevens‐Johnson syndrome/toxic epidermal necrolysis in a dog
Abstract Stevens‒Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a rare, severe skin and mucocutaneous reaction, characterised by extensive epidermal necrosis and skin sloughing. Drugs are common triggers, with reactions to a number of classes reported.
Matt McHale +3 more
wiley +1 more source
Concurrent paraneoplastic dermatomyositis and Sweet syndrome
Alyssa M. Jobe, BS +5 more
doaj +1 more source
Extensive Pustular Tinea Incognita During Late Pregnancy: A Case Report. [PDF]
Vilela BF, Fialho MC, Neves JM.
europepmc +1 more source
Perineal vulvar squamous cell carcinoma was identified in 147 of 571 cases. Owing to the anatomical proximity of these tumors to the anus, treatment selection may present considerable clinical challenges. The majority of patients (53%) underwent surgical treatment alone, whereas 23% received surgery combined with adjuvant radiotherapy and 24% were ...
Karin Kjölhede +4 more
wiley +1 more source
Acquired Palmoplantar Keratoderma Revealing Primary Biliary Cholangitis: Therapeutic Response to Ursodeoxycholic Acid. [PDF]
Dahmani H +3 more
europepmc +1 more source
Discoid Lupus Erythematosus in Genital Skin: A Case Report and Review of the Literature
ABSTRACT Background Discoid lupus erythematosus (DLE) represents the most common variant of chronic cutaneous lupus erythematosus, a skin‐specific autoimmune disorder within the broader lupus erythematosus spectrum Clinically, DLE is characterized by erythematous, scaly plaques with areas of hyperpigmentation.
Ala' Abu‐Dayeh +2 more
wiley +1 more source
Targeting type 2 inflammation in dermatology: mechanisms and clinical implications. [PDF]
Khalil N, Farhadi L, Yosipovitch G.
europepmc +1 more source
Dermatologic Toxicities Associated With Novel Pan‐RAS/RAF Inhibitors
ABSTRACT Background The mitogen‐activated protein kinase (MAPK) pathway plays a key role in cell‐cycle regulation and tumor progression in cancer. Dermatologic toxicities (DTs) to newer pan‐RAS (RMC‐6236) and pan‐RAF (LXH254/naporafenib) inhibitors are emerging.
Lin J. He +11 more
wiley +1 more source

